Alliance for Pandemic Preparedness

December 23, 2020

Evaluating the Efficacy of COVID-19 Vaccines

Category:

Topic:

Keywords (Tags): , , ,

Using dual or triple primary endpoints that include SARS-CoV-2 infection, symptomatic infection and severe COVID-19 could speed up characterization and licensure of vaccines for SARS-CoV-2, according to models of placebo controlled-vaccine trials. The authors suggest that dual or triple primary endpoints could speed up the discovery, characterization, and licensure of effective vaccines by creating data that would allow for more rapid interim evaluations and more precise confidence intervals. 

Lin et al. (Dec 19, 2020). Evaluating the Efficacy of COVID-19 Vaccines. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1863